Rocket


Overview
Financials
News + Filings
Key Docs
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
VBI Vaccines Inc (VBIV) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/14/2023 8-K Quarterly results
Docs: "VBI Vaccines Reports Second Quarter 2023 Financial Results"
07/27/2023 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
07/24/2023 8-K Quarterly results
07/19/2023 8-K Quarterly results
07/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "160 Second Street, Floor 3",
"160 Second Street, Floor 3"
07/05/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Subsidiaries",
"VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties"
06/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "VBI Vaccines Announces Poster Presentation at EASL 2023"
05/15/2023 8-K Quarterly results
Docs: "VBI Vaccines Reports First Quarter 2023 Financial Results"
04/28/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/04/2023 8-K Material Modifications to Rights of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appo...
Docs: "EMPLOYMENT AGREEMENT This Employment Agreement is made as of April 3, 2023 by and between Nell Beattie, on the one hand , and VBI Vaccines Inc., a Delaware corporation , on the other hand. WHEREAS, the Executive has been an Executive and an Officer of the Company, as Chief Business Officer, since September 21, 2017 ; and WHEREAS, the Executive will assume a new role and title of Chief Financial Officer and Head of Corporate Development effective April 10, 2023; and WHEREAS, the Company and the Executive desire to set forth, in a definitive employment agreement, their respective rights and obligations with respect to the Executive’ s employment by the Company; and WHEREAS, the Executive is a key employee of the Company with significant access to information concerning the Company, its subsi...",
"VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split"
03/13/2023 8-K Quarterly results
Docs: "VBI Vaccines Reports Full Year 2022 Financial Results"
02/28/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
12/30/2022 8-K Quarterly results
12/27/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
12/08/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/20/2022 8-K Quarterly results
10/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Anti-PD-1 Balstilimab in a Phase 2 Study in Primary Glioblastoma Patients"
09/29/2022 8-K Quarterly results
09/21/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting"
09/15/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of",
"Company: VBI Vaccines Inc., a corporation existing pursuant to the laws of British Columbia. Class of Stock: Common Stock Number of Warrant Shares: A number equal to the Warrant Coverage Amount divided by the Warrant Price, as in effect from time to time. Warrant Coverage Amount: A number equal to the aggregate original principal amount of the Term Loans actually funded by Lenders pursuant to the Loan Agreement, multiplied by 3.50% pursuant to the Loan Agreement. Warrant Price: $0.8026 Issue Date: September 14, 2022 Expiration Date: 10 years from the Issue Date. Loan Agreement: This Warrant to Purchase Shares of Common Stock is issued in connection with, and as consideration of the commitments pursuant to, that certain Second Amendment to Loan and Guaranty Agreement and Affirmation of Pled...",
"VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures"
09/09/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/08/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®"
08/26/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
08/08/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
07/01/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy